Status:
COMPLETED
Escitalopram as a Mood Stabilizer for Bipolar II Disorder
Lead Sponsor:
The University of New South Wales
Conditions:
Bipolar Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will investigate the efficacy of Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI) antidepressant, in the treatment of Bipolar II Disorder. The use of antidepressants for those...
Detailed Description
This study is a randomized, double-blind, placebo-controlled, cross-over trial of Escitalopram (10 mg) versus placebo (identical presentation) in subjects identified as having Bipolar II Disorder. The...
Eligibility Criteria
Inclusion
- Aged 18-65
- Minimum two year history of depressive and hypomanic episodes
- Mood episodes occuring monthly
- Meet DSM-IV criteria for Bipolar II Disorder (with exception of minimum 4 day period for hypomanic episodes)
Exclusion
- Previous treatment with any antidepressant, mood stabilizer or neuroleptic medication
- History of psychotic symptoms during hypomanic or depressive episodes
- Current suicidal behaviours
- Current substantive illicit drug use or alcohol consumption
- Significant personality disorder
- Pregnancy or breastfeeding
- History of heart disease, liver disease, epilepsy or seizures
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00156325
Start Date
February 1 2004
End Date
February 1 2005
Last Update
January 2 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New South Wales
Sydney, New South Wales, Australia, 2031